Abcellera Biologics 

Yahoo Finance • 8 days ago

Sector Update: Health Care Stocks Rise Late Afternoon

Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index and the State Stree PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 8 days ago

AbCellera settles patent litigation with Bruker over microfluidic device tech

[The Patent Application Process Important Paperwork and Necessary Tools for Success] * Bruker Corp. (BRKR [https://seekingalpha.com/symbol/BRKR]) will pay AbCellera Biologics (ABCL [https://seekingalpha.com/symbol/ABCL]) $36M plus futur... Full story

Yahoo Finance • 8 days ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

VANCOUVER, British Columbia, December 18, 2025--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that it has entered into a settlement and patent license agreement with Bruker Corporation, resolving the patent litigation between t... Full story

Yahoo Finance • 29 days ago

MODD, LAB, HOWL, COGT, LGVN, ABCL Lead Biotech After-Hours Rally - Nov 26

(RTTNews) - Several biotech and life sciences companies posted notable gains in after-hours trading on Wednesday, November 26, reflecting investor interest despite a relatively quiet news cycle. Modular Medical, Inc. (MODD) shares surged... Full story

Yahoo Finance • last month

AbCellera Biologics Inc. (ABCL) is a Buy at Stifel Nicolaus despite Wider Q3 Net Loss

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the Canadian penny stocks to buy right now. On November 7, Stifel Nicolaus reiterated a Buy rating on AbCellera Biologics Inc. (NASDAQ:ABCL) and set a $7 price target.AbCellera Biologics Inc... Full story

Yahoo Finance • last month

Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution?

AbCellera Biologics Inc. (NASDAQ:ABCL) is a must-buy penny stock to buy now. On November 13, at the Stifel 2025 Healthcare Conference, AbCellera Biologics Inc. (NASDAQ:ABCL) reaffirmed its strategic evolution into a company focused on deve... Full story

Yahoo Finance • 2 months ago

After-Hours Biotech Watch: IFRX, ABCL, RLYB Among Notable Risers

(RTTNews) - Several biotechnology and pharmaceutical stocks showed notable price increases during Friday's after-hours trading session, with movement driven by upcoming data releases, recent earnings reports, and prior corporate updates.... Full story

Yahoo Finance • 2 months ago

Here are the major earnings after the close Thursday

Major earnings expected after the bell on Thursday include: * Block (XYZ [https://seekingalpha.com/symbol/XYZ]) * The Trade Desk (TTD [https://seekingalpha.com/symbol/TTD]) * Airbnb (ABNB [https://seekingalpha.com/symbol/ABNB]) *... Full story

Yahoo Finance • 3 months ago

Nuvation Bio Inc. (NUVB): A Bull Case Theory

We came across a bullish thesis on Nuvation Bio Inc. on wallstreetbets subreddit by asagi_lumina. In this article, we will summarize the bulls’ thesis on NUVB. Nuvation Bio Inc.'s share was trading at $3.2200 as of September 23rd.AbCellera... Full story

Yahoo Finance • 3 months ago

TD Cowen Reiterates Buy Rating on ABCL After AbCellera Biologics Dosed First Participants of ABCL575

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On September 11, TD Cowen reiterated its Buy rating on AbCellera Biologics Inc. (NASDAQ:ABCL), without giving a price target.... Full story

Yahoo Finance • 4 months ago

KORU Medical Systems And 2 Other Penny Stocks To Watch For Growth

As the U.S. stock market continues to reach new heights, with major indices like the S&P 500 and Nasdaq Composite hitting all-time highs, investors are increasingly optimistic about future growth prospects. In this context, penny stocks—th... Full story

Yahoo Finance • 5 months ago

AbCellera signals clinical-stage transition with first patient dosing for ABCL635 and targets mid-2026 data milestone

Earnings Call Insights: AbCellera Biologics Inc. (ABCL) Q2 2025 MANAGEMENT VIEW * CEO Carl L.G. Hansen announced, "This quarter, we achieved a major company milestone, receiving Health Canada authorization to initiate AbCellera's first... Full story

Yahoo Finance • 5 months ago

Curious about the stocks that are showing activity after the closing bell on Thursday?

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. [postmarket] GAINERS TICKER CHANGE COMMENT MRM [https://www.chartmill.com/stock/quote/MRM/profile] 56.67% ME... Full story

Yahoo Finance • 5 months ago

Leerink Partners Affirms Outperform Rating on AbCellera Biologics (ABCL) Following Pivot

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the top high-return penny stocks to buy now. On July 7, Leerink Partners resumed coverage of the stock with an ‘Outperform’ rating and a $5 price target. The research firm remains confident... Full story

Yahoo Finance • 5 months ago

Abcellera Biologics stock hits 52-week high at $4.46

Abcellera Biologics Inc. stock reached a 52-week high, hitting $4.46, showcasing a significant milestone for the company. With a market capitalization of $1.33 billion, the biotech company maintains strong liquidity, as evidenced by its im... Full story

Yahoo Finance • 6 months ago

Abcellera Biologics stock hits 52-week high at 4.09 USD

Abcellera Biologics Inc. (ABCL) stock reached a 52-week high, trading at 4.09 USD. This milestone comes as the company experiences a significant 1-year change, with its stock appreciating by 46%. According to InvestingPro data, technical i... Full story

Yahoo Finance • 6 months ago

Truist Financial Lowers PT on AbCellera Biologics (ABCL) to $10 From $28, Keeps a Buy Rating

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the 13 Stocks Under $5 With High Upside Potential. On May 16, Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on AbCellera Biologics Inc. (NASDAQ:ABCL), lowering the pr... Full story

Yahoo Finance • 6 months ago

Leerink Partners assumes coverage on AbCellera stock with Outperform rating

Investing.com - Leerink Partners has assumed coverage on AbCellera Biologics (NASDAQ:ABCL) with an Outperform rating and a $5.00 price target, according to a research note released Monday. The stock has shown strong momentum recently, gain... Full story

Yahoo Finance • 7 months ago

AbCellera Biologics Inc. (ABCL): A Bull Case Theory

We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Investment Ides by Antonio’s Substack. In this article, we will summarize the bulls’ thesis on ABCL. AbCellera Biologics Inc. (ABCL)'s share was trading at $2.14 as of 2... Full story

Yahoo Finance • 7 months ago

Why AbCellera Biologics Stock Raced Nearly 6% Higher Today

Investors were surely discovering drug discovery company AbCellera Biologics(NASDAQ: ABCL) as the trading week kicked off on Monday. On encouraging news in an important North American jurisdiction, those folks bid the biotech's stock up by... Full story